Study wrapper · #942
Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
Abdelrahman RM, Musa TH, Arbab IA, et al. Journal of obesity. 2025.
DOI: 10.1155/jobe/9919810PubMed: 41333115
Editor's note
This review surveys the current and near-future GLP-1 landscape for obesity, discussing tolerability, access, and expanding indications. Semaglutide and tirzepatide are covered as approved agents with retatrutide among the pipeline drugs. A broad background piece with some forward-looking speculation.
Plain-language abstract
A narrative review of GLP-1 receptor agonists for obesity, covering efficacy, safety, adherence challenges, and emerging agents including semaglutide, tirzepatide, and retatrutide.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026